Literature DB >> 31235486

Arylacetamide Deacetylase Enzyme: Presence and Interindividual Variability in Human Lungs.

Morena Gabriele1, Paola Puccini1, Marco Lucchi1, Vittorio Aprile1, Pier Giovanni Gervasi1, Vincenzo Longo2.   

Abstract

Human arylacetamide deacetylase (AADAC) is a single microsomal serine esterase involved in the hydrolysis of many acetyl-containing drugs. To date, the presence and activity of the AADAC enzyme in human lungs has been scarcely examined. We investigated its gene and protein expression as well as interindividual variations in AADAC activities in a large number of human lungs (n = 25) using phenacetin as a selective substrate. The kinetic parameters K m and V max were determined. Our findings highlighted a high interindividual variability in both AADAC mRNA levels and hydrolysis activities. Furthermore, for the first time we demonstrated the presence of the AADAC protein in various lung samples by means of immunoblot analysis. As a comparison, phenacetin hydrolysis was detected in pooled human liver microsomes. Lung activities were much lower than those found in the liver. However, similar K m values were found, which suggests that this hydrolysis could be due to the same enzyme. Pulmonary phenacetin hydrolysis proved to be positively correlated with AADAC mRNA (*P < 0.05) and protein (*P < 0.05) levels. Moreover, the average values of AADAC activity in smokers was significantly higher than in nonsmoker subjects (*P < 0.05), and this might have an important role in the administration of some drugs. These findings add more information to our knowledge of pulmonary enzymes and could be particularly useful in the design and preclinical development of inhaled drugs. SIGNIFICANCE STATEMENT: This study investigated the presence and activity of the AADAC enzyme in several human lungs. Our results highlight high interindividual variability in both AADAC gene and protein expression as well as in phenacetin hydrolysis activity. These findings add more information to our knowledge of pulmonary enzymes and could be particularly useful in the design and preclinical development of inhaled drugs.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31235486     DOI: 10.1124/dmd.119.087031

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  2 in total

1.  AADAC promotes therapeutic activity of cisplatin and imatinib against ovarian cancer cells.

Authors:  Haijing Wang; Disong Wang; Tingting Gu; Mengjiao Zhu; Ling Cheng; Wentao Dai
Journal:  Histol Histopathol       Date:  2022-04-22       Impact factor: 2.130

Review 2.  Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review.

Authors:  Tesemma Sileshi; Gosaye Mekonen; Eyasu Makonnen; Eleni Aklillu
Journal:  Pharmgenomics Pers Med       Date:  2022-06-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.